Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2025CancersOpen Access

CAR-T Cell Therapies in B-Cell Acute Lymphoblastic Leukemia: Emerging Data and Open Issues

View Full Paper
Ask AI
Bookmark
Share

Authors

CACaterina AlatiMPMartina PiteaMMMatteo Molica

Discussion

Loading...

Member takes

Overview

Observational data shows overall survival rates of 60-80% in B-ALL patients, indicating areas for improvement.

Key Points

  • One-year overall survival rates after CAR-T therapy range from 60% to 80%, which is significant for B-ALL.
  • Event-free survival rates hover around 50-70%, with 40-50% of patients achieving remission by the two-year mark.
  • Modern trials focus on consolidating CAR-T therapy for high-risk B-ALL patients, enhancing treatment protocols.
  • Improving gene-editing techniques could lead to more efficient CAR-T cell production, potentially lowering costs.

Cite This Study

Alati et al. (2025) studied this question.

synapsesocial.com/papers/68d42c51713b0b5dfea6f870https://doi.org/10.3390/cancers17183027
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and Safety of CAR T-cell Therapy in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis2025
  2. 2Chimeric Antigen Receptor T-cell Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: Efficacy, Safety, and Future Directions2025 · 1 citations
  3. 3[Current state of CAR-T cell therapy for relapsed/refractory ALL in children and young adults].2025
  4. 4CAR-T-Zell-Therapie bei der akuten lymphoblastischen Leukämie2025
  5. 5Outcomes with chimeric antigen receptor-t cell therapy in relapsed/refractory b-cell acute lymphoblastic leukemia: A systematic review and meta-analysis2025